Products
Picankibart Biosimilar Monoclonal Antibody (IL-23 p19) for Research
Cat No.: GMP-Bios-INN-1336
Anti-IL23A therapeutic antibody (Pre-made Picankibart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Picankibart (development code IBI-112) is a monoclonal antibody targeting IL-23 subunit alpha (IL23A). It is developed by Innovent Biologics for Plaque psoriasis, Ulcerative colitis, Autoimmune disorders et al. in preregistration development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1336-1mg | 1mg | 3090 |
| GMP-Bios-INN-1336-10mg | 10mg | |
| GMP-Bios-INN-1336-100mg | 100mg | |
| GMP-Bios-INN-1336-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Picankibart biosimilar, Whole mAb, Anti-IL23A Antibody: Anti-IL-23 p19/NeutraControl IL-23 p19/IL23A/IL23 therapeutic antibody |
| INN Name | Picankibart |
| Target | IL23A |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Preregistration |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2023 |
| Year Recommended | 2023 |
| Companies | Innovent Biologics |
| Conditions Approved | na |
| Conditions Active | Plaque psoriasis;Ulcerative colitis;Autoimmune disorders;Gastrointestinal disorders |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
